For how we live.
Every article we have published on Interventional Cardiology, newest first.
In the PROGRESS trial, 744 patients with moderate aortic stenosis and an at-risk feature got early TAVR or clinical surveillance. Death or a heart-failure event at two years fell from 23.9% to 16.7%.
In the P4 trial, 1105 patients having coronary stents placed were randomised to planning by CT angiography or by intravascular ultrasound. Target-vessel failure at one year was 4.1% versus 4.6% — non-inferior.
A Swiss investigator-led trial tested whether isolating the back wall of the left atrium on top of pulsed-field pulmonary vein isolation cuts arrhythmia recurrence. The primary answer was no.
In 264 patients in China, the device maker's trial reported clinical worsening in 25.7% versus 51.5% on medical therapy alone (HR 0.49) — but no sham procedure blinded patients.
PRAGUE-26 randomised 558 patients across 11 Czech hospitals. The seven-day composite fell from 6.8% to 0.7%, driven by cardiorespiratory collapse, with no clear bleeding penalty.